You are here: Industry Insights > 3SBio

News List

Sunshine Guojian Selects Verseau's VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration prnasia
December 15, 2020
3SBio Inc.'s subsidiary, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4, as a licensed program under their partnership agreement focused on the ...
3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212 prnasia
November 24, 2020
Chinese leading biopharmaceutical company, 3SBio Inc., announced today that Selecta Biosciences, Inc., the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of ...
Numab closes $23.6m Series B round led by Asian investors pharmaceutical-technology
March 11, 2020
Swiss biotech Numab has raised CHF22m ($22.7m) in a Series B financing round, which attracted multiple new investors from Asia, including 3SBio, Mitsubishi UFJ Capital and Eisai, as well as a company board member Dr Daniel Vasella.
3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research prnasia
March 02, 2020
The collaboration of INV and IRF is a unique, first of its kind, impact investing collaboration.
3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research prnasia
March 01, 2020
The collaboration of INV and IRF is a unique, first of its kind, impact investing collaboration.
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration En-CPhI.CN
November 18, 2019
3SBio Inc. and Verseau Therapeutics, Inc. announced the selection of VTX-0811, a monoclonal antibody targeting PSGL-1, as the first licensed program under their partnership agreement focused ...
3SBio, TLC to commercialize two NanoX products in China biospectrumasia
March 04, 2019
Under the terms of the agreement, TLC is eligible to receive up to US$25 million in upfront payments for each product and subsequent regulatory and sales milestone payments.
3SBio Unveils 2017 Annual Results: Revenue Soars by 33.5% prnasia
March 27, 2018
Leading Chinese biotechnology company 3SBio (01530.HK) today released its 2017 annual results, showing that the company has been dramatically growing with important progress made in all businesses.
CFDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Type-2 Diabetes Patients prnasia
January 05, 2018
3Sbio Incannounced today that China's first Glucagon-like peptide-1 receptor agonist weekly preparation Bydureon® has been formally approved by China Food and Drug Administration , as a new treatment option to improve glycemic control for patients with ty
3SBio Acquires Therapure for $290M contractpharma
September 06, 2017
3SBio Inc., a Chinese biopharmaceutical company, through a joint venture formed with CPE Funds, has acquired the CDMO business of Canada-based biologics manufacturer Therapure Biopharma for $290 million.

Previous page 1 2 Next page